Get the Stockscreener App
2.18
6.03%
-0.14
After Hours:
2.15
-0.03
-1.38%
Dermata Therapeutics Inc stock is traded at $2.18, with a volume of 603.22K.
It is down -6.03% in the last 24 hours and down -27.09% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$2.32
Open:
$2.15
24h Volume:
603.22K
Relative Volume:
0.68
Market Cap:
$2.24M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.1018
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
+17.20%
1M Performance:
-27.09%
6M Performance:
-67.32%
1Y Performance:
-84.32%
1-Day Range:
$2.06
$2.70
1-Week Range:
$1.58
$2.70
52-Week Range:
$1.58
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
2.18 | 2.38M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Dermata Therapeutics Inc Equity Warrant Stock Analysis and ForecastBullish Engulfing Patterns & Free Phenomenal Capital Appreciation - earlytimes.in
Dermata Therapeutics announces $2.55M private offering - MSN
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top 5 stocks to watch today | December 30th - MSN
Dermata Therapeutics: Is Change on the Horizon? - StocksToTrade
Dermata Therapeutics: Unveiling Bold Moves - timothysykes.com
Top 5 Stocks To Watch Today | December 30th - MSN
Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus - Benzinga
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Dermata stock surges after closing $4.1 million private placement By Investing.com - Investing.com Nigeria
Dermata stock surges after closing $4.1 million private placement - Investing.com
Dermata Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Weatherford Democrat
Skincare firm Dermata raises $4.1M to back new over-the-counter acne kit - Stock Titan
Bank Watch: Why Dermata Therapeutics Inc Equity Warrant stock is popular among millennialsQuarterly Profit Report & High Accuracy Investment Entry Signals - moha.gov.vn
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Fox21Online
Dermata Therapeutics, Inc.Warrant (NQ: DRMAW - FinancialContent
Dermata Therapeutics’ Skincare Innovation Sparks Interest - StocksToTrade
Dermata Therapeutics, Inc. (DRMA) Stock: Surges 25% as Insider-Backed $4.1M Offering Fuels Momentum - parameter.io
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is Dermata Therapeutics Stock Surging Wednesday? - Sahm
Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today? - Menafn.com
Dermata Therapeutics stock soars after securing $4.1 million private placement By Investing.com - Investing.com Nigeria
Dermata Therapeutics stock soars after securing $4.1 million private placement - Investing.com Nigeria
DRMA Stocks Thrive: Time for Action? - timothysykes.com
Why did Dermata Therapeutics stock surge 22% pre-market today? - MSN
Dermata lines up as much as $12.4M to help launch OTC acne kit - Stock Titan
Ingersoll (500210) Stock RalliesVolume Profile Analysis & Investment Recommendations You Can Trust - Bollywood Helpline
Dermata Therapeutics, Inc. announced that it expects to receive $4.124468 million in funding - marketscreener.com
Can Dermata Therapeutics Inc. Equity Warrant stock deliver consistent earnings growthTrade Volume Report & Smart Money Movement Alerts - Улправда
Quarterly Risk: How interest rate cuts could boost ESGRO stockJuly 2025 Market Mood & Free Verified High Yield Trade Plans - Улправда
Will Dermata Therapeutics Inc. stock reach all time highs in 20252025 Trading Volume Trends & Stock Portfolio Risk Management - Улправда
How buybacks impact Dermata Therapeutics Inc. stock valueLayoff News & Community Supported Trade Ideas - Улправда
Why Dermata Therapeutics Inc. Equity Warrant stock could rally in 2025Quarterly Portfolio Report & Accurate Entry/Exit Alerts - Улправда
Is Dermata Therapeutics Inc. stock vulnerable to regulatory risksJuly 2025 Intraday Action & Expert Approved Trade Ideas - Улправда
Is Dermata Therapeutics Inc. stock a contrarian buyJuly 2025 Intraday Action & Stock Portfolio Risk Control - Улправда
Will Dermata Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Precise Swing Trade Alerts - Улправда
Why Dermata Therapeutics Inc. Equity Warrant stock is popular among millennialsTake Profit & Weekly Watchlist for Hot Stocks - DonanımHaber
Will Dermata Therapeutics Inc. stock outperform growth indexesWeekly Trade Review & Expert Curated Trade Setups - DonanımHaber
Why Dermata Therapeutics Inc. Equity Warrant stock remains undervaluedCEO Change & Weekly High Potential Alerts - Bölüm Sonu Canavarı
Will Dermata Therapeutics Inc. stock attract more institutional investorsJuly 2025 Momentum & Comprehensive Market Scan Reports - DonanımHaber
Growth Value: Will Dermata Therapeutics Inc. Equity Warrant stock gain from lower inflation2025 Macro Impact & Low Volatility Stock Recommendations - DonanımHaber
Dermata Therapeutics Earnings Notes - Trefis
Support Test: Will Dermata Therapeutics Inc. stock deliver shareholder valueJuly 2025 Gainers & Accurate Intraday Trading Signals - DonanımHaber
Does POWL stock trade at a discount to peers2025 EndofYear Setup & Daily Technical Stock Forecast Reports - Bollywood Helpline
Acne Vulgaris Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight - openPR.com
Total debt of Dermata Therapeutics Inc Warrant 2021- on Dermata Therapeutics – BOATS:DRMAW - TradingView — Track All Markets
Check Out Dermata Therapeutics Inc (DRMA)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Aug Weekly: What technical signals suggest for IKNA stockMarket Risk Report & Scalable Portfolio Growth Methods - BỘ NỘI VỤ
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):